Canagliflozin Ameliorates Nonalcoholic Fatty Liver Disease by Regulating Lipid Metabolism and Inhibiting Inflammation through Induction of Autophagy

PURPOSE: Nonalcoholic fatty liver disease (NAFLD) is closely associated with metabolic diseases, including obesity and diabetes, and has gradually become the most common cause of chronic liver disease. We investigated the effects of sodium glucose cotransporter 2 (SGLT2) inhibitor canagliflozin on N...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Zhipeng, Hu, Wenxin, Wang, Bin, Xu, Ting, Wang, Jianning, Wei, Dan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Yonsei University College of Medicine 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9226837/
https://www.ncbi.nlm.nih.gov/pubmed/35748073
http://dx.doi.org/10.3349/ymj.2022.63.7.619

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9226837/
https://www.ncbi.nlm.nih.gov/pubmed/35748073
http://dx.doi.org/10.3349/ymj.2022.63.7.619

Ejemplares similares